Biotechnology Services

We get it. Turning on two-factor authentication for your online accounts can be a pain. But like going to the dentist, it’s just something you have to do.On Tuesday, someone broke into the Securities and Exchange Commission’s official X account and tweeted that spot bitcoin exchange-traded funds had been approved, sending the price of the cryptocurrency briefly higher. The official-looking announcement was a hack, an SEC spokeswoman said; the agency did officially approve the ETFs on Wednesday. Copyright ©2024Dow Jones…

Updated Jan. 9, 2024 2:35 am ETGSKsaid it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the…

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Johnson & Johnson will acquire cancer-treatment developer AmbrxBiopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the…

Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.Merck on Monday said it will pay $23 a share in cash for Harpoon, more than double Friday’s closing price of $10.55 for the South San Francisco, Calif., company.Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeuticsfor about $680 million.Merck on Monday said…

A federal appeals court said the U.S. government was right to challenge Illumina’s purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission for reconsideration.A three-judge panel found the deal to be anticompetitive, but said the FTC erred in how it considered Illumina’s proposed fix for its drawbacks. The judges ordered the FTC to reconsider its opinion on the troubled deal, which the European Commission has already ordered Illumina to unwind.Copyright ©2023Dow Jones &…

The recent breach of 23andMeuser accounts shows a simple yet powerful truth about data security: Don’t reuse passwords, people.The DNA test-kit company on Monday reported a hacker accessed 14,000 accounts because of password reuse, exposing information belonging to approximately 6.9 million people. The 23andMe computer network wasn’t breached and wasn’t the source of these compromised credentials, a company spokesman said in a statement. The company first disclosed the incident in October and has been investigating since…

The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you…

The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their…

China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to…

Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all…